5 Key Takeaways
-
1
The Roving Reporter series discusses the maturation of cell and gene therapy at ASGCT 2026 in Boston.
-
2
Companies are focusing on regulatory expectations, manufacturing scalability, and patient access as therapies approach routine clinical use.
-
3
Sustainable commercialization strategies are becoming crucial for expanding therapies beyond rare diseases.
-
4
Insights from industry leaders highlight the importance of investment decisions and collaboration in advancing therapies.
-
5
The discussion emphasizes the role of manufacturing innovation and platform technologies in shaping the future of advanced therapies.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
